WO2007075377A3 - Certain chemical entities, compositions and methods - Google Patents

Certain chemical entities, compositions and methods Download PDF

Info

Publication number
WO2007075377A3
WO2007075377A3 PCT/US2006/047827 US2006047827W WO2007075377A3 WO 2007075377 A3 WO2007075377 A3 WO 2007075377A3 US 2006047827 W US2006047827 W US 2006047827W WO 2007075377 A3 WO2007075377 A3 WO 2007075377A3
Authority
WO
WIPO (PCT)
Prior art keywords
skeletal
troponin
muscle
post
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/047827
Other languages
French (fr)
Other versions
WO2007075377A2 (en
Inventor
Bradley P Morgan
Fady Malik
David J Morgans Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Priority to EP06845482A priority Critical patent/EP1959947A2/en
Publication of WO2007075377A2 publication Critical patent/WO2007075377A2/en
Anticipated expiration legal-status Critical
Publication of WO2007075377A3 publication Critical patent/WO2007075377A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, familial or acquired myopathies or muscular dystrophies), post-surgical and post-traumatic muscle weakness, and other conditions.
PCT/US2006/047827 2005-12-15 2006-12-13 Certain chemical entities, compositions and methods Ceased WO2007075377A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06845482A EP1959947A2 (en) 2005-12-15 2006-12-13 Certain chemical entities, compositions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75103205P 2005-12-15 2005-12-15
US60/751,032 2005-12-15

Publications (2)

Publication Number Publication Date
WO2007075377A2 WO2007075377A2 (en) 2007-07-05
WO2007075377A3 true WO2007075377A3 (en) 2008-11-20

Family

ID=38218438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047827 Ceased WO2007075377A2 (en) 2005-12-15 2006-12-13 Certain chemical entities, compositions and methods

Country Status (3)

Country Link
US (2) US20070197505A1 (en)
EP (1) EP1959947A2 (en)
WO (1) WO2007075377A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552236T1 (en) * 2003-01-14 2012-04-15 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE
ES2522579T3 (en) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compounds, compositions and methods
ES2419007T3 (en) * 2005-12-15 2013-08-19 Cytokinetics, Inc. Certain chemical entities, compositions and procedures
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
JP2011520809A (en) * 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド Urea compounds as gamma secretase modulators
FR2947546B1 (en) * 2009-07-03 2011-07-01 Sanofi Aventis PYRAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
KR20250075704A (en) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. Long-acting parathyroid hormone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284453A (en) * 1964-09-29 1966-11-08 American Cyanamid Co 4-(2-aroylethyl)-1-piperazinecarboxylic acid esters
US6908923B2 (en) * 2001-12-21 2005-06-21 Cytokinetics, Inc. Compositions and methods for treating heart failure
US6916814B2 (en) * 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939169A (en) * 1971-03-29 1976-02-17 Imperial Chemical Industries Limited Alkylene bis(pyridiniumareylene quaternary salts)
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
AU4028393A (en) * 1992-05-28 1993-12-30 Pfizer Inc. New (N)-aryl and (N)-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (ACAT)
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6262083B1 (en) * 1997-11-05 2001-07-17 Choongwae Pharma Corporation Genipin derivative having liver protection activity
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
AU3707600A (en) * 1999-03-01 2000-09-21 Regents Of The University Of California, The Thiacrown polymers for removal of mercury from waste streams
DE19921498A1 (en) * 1999-05-08 2000-11-16 Clariant Gmbh Process for the preparation of aqueous diazonium salt solutions
CA2374737C (en) * 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US6656971B2 (en) * 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
GB0117950D0 (en) * 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
ATE552236T1 (en) * 2003-01-14 2012-04-15 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
ES2522579T3 (en) * 2004-06-17 2014-11-17 Cytokinetics, Inc. Compounds, compositions and methods
US7176222B2 (en) * 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
ES2419007T3 (en) * 2005-12-15 2013-08-19 Cytokinetics, Inc. Certain chemical entities, compositions and procedures
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284453A (en) * 1964-09-29 1966-11-08 American Cyanamid Co 4-(2-aroylethyl)-1-piperazinecarboxylic acid esters
US6916814B2 (en) * 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
US6908923B2 (en) * 2001-12-21 2005-06-21 Cytokinetics, Inc. Compositions and methods for treating heart failure

Also Published As

Publication number Publication date
WO2007075377A2 (en) 2007-07-05
US20090247544A1 (en) 2009-10-01
EP1959947A2 (en) 2008-08-27
US20070197505A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
WO2007075377A3 (en) Certain chemical entities, compositions and methods
WO2008016669A3 (en) Certain chemical entities, compositions and methods
WO2008016648A3 (en) Certain chemical entities, compositions and methods
WO2006017055A3 (en) Pyrazole amide derivatives, compositions containing such compounds and methods of use
AP2005003424A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them.
AP2006003633A0 (en) Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2003263393A1 (en) New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2005007658A3 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005033102A3 (en) Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
NO20091700L (en) Florizine analogues as inhibitors of glucose co-transporter 2
DK1474425T3 (en) Deazapurins and uses thereof
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
PT1902037E (en) 2,4-diamino-pyrimidines used as aurora inhibitors
WO2008005303A3 (en) Thiazolopyrimidine modulators of trpv1
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
SI1711184T1 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
WO2006020959A3 (en) Substituted benzofused heterocycles
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
NO20051503L (en) Pyrazolopyridines and processes for the preparation and use of the same.
WO2008045406A3 (en) Compounds, screens, and methods of treatment
EP1188769A8 (en) High resolution crystal structure of the ribosome and design of protein synthesis inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006845482

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE